The Question Everyone Is Actually Asking
If you have searched "what is a microdose of semaglutide" or "what is considered a microdose of semaglutide," you are not looking for marketing. You are looking for a number. Specifically, the dose range that distinguishes a microdose protocol from standard GLP-1 dosing, and whether that lower dose is worth it for your situation. This article gives you the number, the tradeoffs, and the honest version of who benefits from a microdose approach and who does not.
Educational content. Not medical advice. A licensed-provider evaluation determines what is right for any individual patient.
The Short Answer
A microdose of semaglutide is generally any weekly dose below the FDA-approved starter dose of 0.25 mg. In practice, compounded microdose semaglutide protocols typically fall in the range of 0.05 mg to 0.20 mg per week, with some patients beginning as low as 0.025 mg. The standard semaglutide protocol used in Wegovy and Ozempic starts at 0.25 mg weekly and titrates up to a maintenance range of 1.7 mg to 2.4 mg weekly. A microdose sits well below that starter dose and often stays there.
The term itself is not defined by the FDA. It is a clinical convention that emerged from compounding pharmacy practice and from providers who wanted a lower-dose entry point for sensitive patients or a maintenance option for patients who had already reached their weight-loss goals.
Standard Dose vs Microdose Side by Side
| Standard semaglutide (Wegovy) | Microdose semaglutide | |
|---|---|---|
| Starting dose | 0.25 mg/week | 0.05 to 0.10 mg/week (commonly) |
| Typical maintenance | 1.7 to 2.4 mg/week | 0.10 to 0.25 mg/week |
| Titration interval | Every 4 weeks | Slower, provider-guided |
| Average weight loss (6 months) | ~10 to 15 percent of body weight | ~3 to 8 percent of body weight |
| Side-effect intensity | Moderate; nausea common during titration | Generally milder |
| Madison Meds compounded pricing | From $99 first month (code SAVENOW), $169 ongoing | From $99 first month (code SAVENOW), $125 ongoing |
The numbers in the weight-loss row are approximate. Standard-dose figures reflect the STEP 1 trial average for adults with obesity at 68 weeks on semaglutide 2.4 mg. Microdose figures are based on clinical observation and aggregated reports from compounded GLP-1 practices; randomized trial data specific to microdose protocols are limited. Outcomes are individual.
Why Microdose at All?
Microdose semaglutide is a genuine clinical option, not a gimmick, and it has been increasingly studied in research for use cases beyond what the standard dose was originally designed for. There are five common reasons a licensed provider might consider a microdose protocol for an eligible patient:
- Side effect sensitivity. Some patients experience significant nausea, reflux, or fatigue on standard starter doses. A microdose entry point can preserve the appetite-regulation benefit while reducing the intensity of GI effects during the first weeks.
- Modest weight-loss goals. A patient who wants to lose 10 to 20 pounds is not in the same population as a patient with a 60-pound goal. Microdose protocols are often well-matched to smaller goals.
- Maintenance after weight loss. Patients who reached their goal on standard-dose therapy and want to maintain rather than continue losing sometimes step down to a microdose. This is one of the more rapidly growing use cases.
- Metabolic and appetite-regulation support. Some patients use low-dose GLP-1 not primarily for weight loss but to support glucose control, reduce "food noise," or support insulin sensitivity in coordination with their broader plan.
- Cost considerations. Lower dose means lower active ingredient cost per month. Microdose compounded protocols are often the most accessible price tier.
Off-Label Notice
Microdosing GLP-1 medications is an off-label practice not approved by the FDA. No dose below the lowest FDA-approved starting dose (0.25 mg for semaglutide, 2.5 mg for tirzepatide) has been tested in a randomized controlled trial for safety or efficacy. Available clinical evidence for subtherapeutic dosing is limited to observational reports, case series, and pharmacokinetic modeling. Any use should occur only after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. Educational content. Not medical advice. Individual results vary.
What the Research Actually Shows
Every published randomized controlled trial for semaglutide in weight management started at 0.25 mg weekly and titrated up. The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults without diabetes and studied 2.4 mg weekly, reporting an average 14.9% body-weight reduction at 68 weeks. The STEP-4 maintenance trial (Rubino et al., JAMA, 2021) then showed that patients who continued the 2.4 mg maintenance dose after a 20-week titration held their loss, while those switched to placebo regained an average 6.9%. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM, 2023) confirmed a 20% reduction in major adverse cardiac events at the same 2.4 mg dose over a median 39.8 months.
No comparable randomized trial data exists for weekly doses of 0.05 mg, 0.10 mg, or 0.20 mg. The FDA Wegovy prescribing information lists 0.25 mg as the lowest studied initiation dose. When licensed providers use a microdose protocol, they are extrapolating from pharmacokinetic data and clinical observation, not from a controlled trial designed to test the microdose specifically. Some patients respond meaningfully at lower doses; some do not. Research is ongoing, and the honest framing is that microdose semaglutide may support metabolic goals for eligible patients under medical supervision, with outcomes that are individual and not equivalent to the trial-documented outcomes of standard-dose therapy.
What a Microdose Does Not Do
Honesty matters here, because the marketing around microdosing has gotten ahead of the evidence in a few places.
- It is not a shortcut to standard-dose results. If a patient's goal requires the average outcome of standard-dose therapy, microdose is unlikely to deliver that. Mechanism dose-response is real.
- It is not "safer" by virtue of being smaller. The same contraindications apply. Personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, severe GI disease, and certain other conditions are still relevant regardless of dose.
- It is not a research-grade protocol you can self-manage. Compounded semaglutide is a prescription product. The microdose protocol is set, monitored, and adjusted through a licensed-provider evaluation.
- It is not the same as Ozempic or Wegovy. Compounded semaglutide is not an FDA-approved drug. It is dispensed by a US-licensed compounding pharmacy under specific federal and state pharmacy regulations.
How a Microdose Protocol Is Set
A typical microdose semaglutide protocol through Madison Meds works like this. A patient completes the intake and shares full medical history. An independent licensed provider in the Madison Meds network reviews the file, conducts a telehealth evaluation, and decides whether the patient is an appropriate candidate for compounded semaglutide. If yes, the provider sets the starting dose, the titration plan, and the follow-up schedule. The medication is dispensed by a US-licensed compounding pharmacy and shipped to the patient. Most starter protocols begin at 0.05 mg or 0.10 mg weekly and are adjusted over the first 8 to 12 weeks based on response and tolerability.
This is different from buying research-grade peptide vials online without a prescription. We have written about that distinction in our piece on prescribed peptides versus research peptides, and the same logic applies to semaglutide.
Microdose Tirzepatide: A Quick Note
You will sometimes see "microdose tirzepatide" discussed in the same conversation. The same idea applies: doses well below the 2.5 mg standard starter, typically in the 0.50 mg to 1.50 mg range, used for patients who want a lower-dose dual-receptor approach. Microdose tirzepatide is a separate protocol with its own dosing math and its own pricing. If you are choosing between microdose semaglutide and microdose tirzepatide, the same logic in our tirzepatide versus semaglutide comparison applies, just scaled down.
What to Expect in the First 90 Days on a Microdose
Patient experiences vary, but here is the general arc most patients describe.
- Weeks 1 to 2. Mild reduction in appetite. Some patients notice less "food noise" within the first week. GI side effects are usually minimal at microdose levels.
- Weeks 3 to 6. Weight loss begins gradually, typically in the range of 0.5 to 1.5 pounds per week. Provider check-in determines whether to hold the dose, slightly increase, or adjust.
- Weeks 7 to 12. A clearer pattern emerges. Patients on a working microdose typically see continued steady loss without major side effects. Patients who are not responding may have their dose adjusted upward by the provider.
Outcomes are individual. Some patients respond beautifully to microdoses; others find they need a higher dose to see meaningful change. The follow-up structure is what keeps the protocol matched to the patient.
Compounded Microdose Semaglutide Through Madison Meds
Through Madison Meds, compounded semaglutide microdose is available to eligible adults after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. The first-month price is $99 with promo code SAVENOW, and ongoing monthly pricing for the microdose program is $125. The standard-dose compounded semaglutide program is similarly priced with the same first-month $99 promotional structure.
Both programs include the licensed-provider visit, the medication, supplies, and discreet home shipping. The protocol is adjusted by your assigned licensed provider through ongoing follow-up visits, so the dose can be raised, lowered, or held based on your response.
Curious if a microdose is right for you?
An independent licensed provider in the Madison Meds network will review your goals and medical history and recommend the right protocol. Compounded semaglutide microdose starts at $99 your first month with code SAVENOW.
See Microdose SemaglutideFrequently Asked Questions
What is considered a microdose of semaglutide?
A microdose of semaglutide generally refers to a weekly dose below the FDA-approved starter dose of 0.25 mg used in Wegovy and Ozempic. Compounded microdose protocols commonly run in the 0.05 mg to 0.20 mg per week range, with some providers starting as low as 0.025 mg. The exact dose is set by a licensed provider based on the patient's goals, history, and response.
How much weight loss can you expect on a microdose of semaglutide?
Microdose semaglutide produces slower and typically smaller average weight loss than full-dose protocols. Many patients report 3 to 8 percent of body weight over six months, compared with the 10 to 15 percent average seen in standard-dose semaglutide trials. Individual results vary based on dose, adherence, nutrition, and activity.
Who is a microdose of semaglutide for?
Microdose semaglutide may be considered for eligible patients who are sensitive to GLP-1 side effects, want a lower-dose entry into therapy, have a modest weight-loss goal, are using GLP-1 therapy primarily for metabolic or appetite-regulation support rather than significant weight loss, or want a maintenance-style protocol after reaching a previous weight goal.
Is microdose semaglutide cheaper than full-dose semaglutide?
Yes. Because the active ingredient quantity per month is lower, compounded microdose semaglutide pricing is typically less expensive than standard-dose compounded semaglutide. Madison Meds compounded semaglutide microdose starts at $99 your first month with promo code SAVENOW.
Can you switch from microdose to a full dose later?
Yes. Many patients start at a microdose for tolerability and titrate upward over time. The licensed-provider evaluation determines when and how to adjust, and the protocol is updated through your follow-up visits. There is no requirement to escalate if the microdose is producing your desired results.
Is microdose semaglutide approved by the FDA?
No. Microdosing semaglutide is an off-label practice. Wegovy and Ozempic are FDA approved starting at a 0.25 mg weekly initiation dose. No dose below 0.25 mg has been tested in a randomized controlled trial for safety or efficacy. Compounded semaglutide microdose protocols are dispensed by US-licensed compounding pharmacies after a licensed-provider evaluation, and any use should occur under medical supervision. Educational content. Not medical advice.
What does the research show about microdose semaglutide?
Every published randomized controlled trial for weight management, including STEP-1 (Wilding et al., NEJM 2021), STEP-4 (Rubino et al., JAMA 2021), and SELECT (Lincoff et al., NEJM 2023), started at 0.25 mg weekly and titrated up to a 2.4 mg maintenance dose. No comparable randomized data exists for subtherapeutic doses below 0.25 mg. Available evidence for microdose protocols is limited to observational reports and pharmacokinetic modeling. Research is ongoing, and outcomes are individual.
Compounded medications are not FDA-approved drugs. This article is Educational content and is Not medical advice. Compounded semaglutide is available through Madison Meds after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. A licensed provider will review your full medical history before any prescription, and not all patients are appropriate candidates for GLP-1 therapy. The dose ranges, weight-loss figures, and timelines discussed are general references; individual results vary and outcomes are individual.